Cargando…

Didymin: an orally active citrus flavonoid for targeting neuroblastoma

Neuroblastoma, a rapidly growing yet treatment responsive cancer, is the third most common cancer of children and the most common solid tumor in infants. Unfortunately, neuroblastoma that has lost p53 function often has a highly treatment-resistant phenotype leading to tragic outcomes. In the contex...

Descripción completa

Detalles Bibliográficos
Autores principales: Singhal, Sharad S., Singhal, Sulabh, Singhal, Preeti, Singhal, Jyotsana, Horne, David, Awasthi, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438742/
https://www.ncbi.nlm.nih.gov/pubmed/28187004
http://dx.doi.org/10.18632/oncotarget.15204
_version_ 1783237834469015552
author Singhal, Sharad S.
Singhal, Sulabh
Singhal, Preeti
Singhal, Jyotsana
Horne, David
Awasthi, Sanjay
author_facet Singhal, Sharad S.
Singhal, Sulabh
Singhal, Preeti
Singhal, Jyotsana
Horne, David
Awasthi, Sanjay
author_sort Singhal, Sharad S.
collection PubMed
description Neuroblastoma, a rapidly growing yet treatment responsive cancer, is the third most common cancer of children and the most common solid tumor in infants. Unfortunately, neuroblastoma that has lost p53 function often has a highly treatment-resistant phenotype leading to tragic outcomes. In the context of neuroblastoma, the functions of p53 and MYCN (which is amplified in ~25% of neuroblastomas) are integrally linked because they are mutually transcriptionally regulated, and because they together regulate the catalytic activity of RNA polymerases. Didymin is a citrus-derived natural compound that kills p53 wild-type as well as drug-resistant p53-mutant neuroblastoma cells in culture. In addition, orally administered didymin causes regression of neuroblastoma xenografts in mouse models, without toxicity to non-malignant cells, neural tissues, or neural stem cells. RKIP is a Raf-inhibitory protein that regulates MYCN activation, is transcriptionally upregulated by didymin, and appears to play a key role in the anti-neuroblastoma actions of didymin. In this review, we discuss how didymin overcomes drug-resistance in p53-mutant neuroblastoma through RKIP-mediated inhibition of MYCN and its effects on GRK2, PKCs, Let-7 micro-RNA, and clathrin-dependent endocytosis by Raf-dependent and -independent mechanisms. In addition, we will discuss studies supporting potential clinical impact and translation of didymin as a low cost, safe, and effective oral agent that could change the current treatment paradigm for refractory neuroblastoma.
format Online
Article
Text
id pubmed-5438742
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-54387422017-05-24 Didymin: an orally active citrus flavonoid for targeting neuroblastoma Singhal, Sharad S. Singhal, Sulabh Singhal, Preeti Singhal, Jyotsana Horne, David Awasthi, Sanjay Oncotarget Review Neuroblastoma, a rapidly growing yet treatment responsive cancer, is the third most common cancer of children and the most common solid tumor in infants. Unfortunately, neuroblastoma that has lost p53 function often has a highly treatment-resistant phenotype leading to tragic outcomes. In the context of neuroblastoma, the functions of p53 and MYCN (which is amplified in ~25% of neuroblastomas) are integrally linked because they are mutually transcriptionally regulated, and because they together regulate the catalytic activity of RNA polymerases. Didymin is a citrus-derived natural compound that kills p53 wild-type as well as drug-resistant p53-mutant neuroblastoma cells in culture. In addition, orally administered didymin causes regression of neuroblastoma xenografts in mouse models, without toxicity to non-malignant cells, neural tissues, or neural stem cells. RKIP is a Raf-inhibitory protein that regulates MYCN activation, is transcriptionally upregulated by didymin, and appears to play a key role in the anti-neuroblastoma actions of didymin. In this review, we discuss how didymin overcomes drug-resistance in p53-mutant neuroblastoma through RKIP-mediated inhibition of MYCN and its effects on GRK2, PKCs, Let-7 micro-RNA, and clathrin-dependent endocytosis by Raf-dependent and -independent mechanisms. In addition, we will discuss studies supporting potential clinical impact and translation of didymin as a low cost, safe, and effective oral agent that could change the current treatment paradigm for refractory neuroblastoma. Impact Journals LLC 2017-02-08 /pmc/articles/PMC5438742/ /pubmed/28187004 http://dx.doi.org/10.18632/oncotarget.15204 Text en Copyright: © 2017 Singhal et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Singhal, Sharad S.
Singhal, Sulabh
Singhal, Preeti
Singhal, Jyotsana
Horne, David
Awasthi, Sanjay
Didymin: an orally active citrus flavonoid for targeting neuroblastoma
title Didymin: an orally active citrus flavonoid for targeting neuroblastoma
title_full Didymin: an orally active citrus flavonoid for targeting neuroblastoma
title_fullStr Didymin: an orally active citrus flavonoid for targeting neuroblastoma
title_full_unstemmed Didymin: an orally active citrus flavonoid for targeting neuroblastoma
title_short Didymin: an orally active citrus flavonoid for targeting neuroblastoma
title_sort didymin: an orally active citrus flavonoid for targeting neuroblastoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438742/
https://www.ncbi.nlm.nih.gov/pubmed/28187004
http://dx.doi.org/10.18632/oncotarget.15204
work_keys_str_mv AT singhalsharads didyminanorallyactivecitrusflavonoidfortargetingneuroblastoma
AT singhalsulabh didyminanorallyactivecitrusflavonoidfortargetingneuroblastoma
AT singhalpreeti didyminanorallyactivecitrusflavonoidfortargetingneuroblastoma
AT singhaljyotsana didyminanorallyactivecitrusflavonoidfortargetingneuroblastoma
AT hornedavid didyminanorallyactivecitrusflavonoidfortargetingneuroblastoma
AT awasthisanjay didyminanorallyactivecitrusflavonoidfortargetingneuroblastoma